{"id":5571,"date":"2023-12-04T05:44:28","date_gmt":"2023-12-04T11:44:28","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5571"},"modified":"2025-06-27T11:27:04","modified_gmt":"2025-06-27T16:27:04","slug":"glenn-sblendorio-as-chairman-of-the-board","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/","title":{"rendered":"Nanoscope Therapeutics contin\u00faa su crecimiento de liderazgo; Da la bienvenida al exitoso l\u00edder de finanzas y biotecnolog\u00eda Glenn Sblendorio como presidente de la junta directiva"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<h3><em>La nueva incorporaci\u00f3n pone de relieve la mejora continua de la trayectoria estrat\u00e9gica de la organizaci\u00f3n.<\/em><\/h3>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><strong>Dallas, TX \u2013 4 de diciembre de 2023 \u2013<\/strong> Nanoscope Therapeutics (Nanoscope), una empresa de biotecnolog\u00eda en etapa cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina, anunci\u00f3 hoy el nombramiento de Glenn Sblendorio como presidente de la junta directiva, con efecto inmediato. Con m\u00e1s de 30 a\u00f1os de experiencia ejemplar marcada por un amplio liderazgo ejecutivo en la industria oft\u00e1lmica, el Sr. Sblendorio apoyar\u00e1 a Nanoscope para alcanzar su visi\u00f3n estrat\u00e9gica.<\/p>\n<p>En su nuevo cargo como presidente de la junta directiva, el Sr. Sblendorio desempe\u00f1ar\u00e1 un papel fundamental para garantizar la eficacia de la junta directiva en la implementaci\u00f3n de la estrategia y direcci\u00f3n organizacional de Nanoscope. Su amplio conocimiento de las finanzas y el desarrollo empresarial ayudar\u00e1 a guiar a Nanoscope en su misi\u00f3n de llevar la esperanza de una vista renovada a millones de personas afectadas por enfermedades degenerativas de la retina para las que actualmente no existen curas.<\/p>\n<p>El Sr. Sblendorio coment\u00f3 sobre su nombramiento: \u201cEs un honor para m\u00ed unirme a Nanoscope como Presidente del Consejo de Administraci\u00f3n. El compromiso de la compa\u00f1\u00eda con el desarrollo de tratamientos innovadores para enfermedades degenerativas de la retina coincide con mi pasi\u00f3n por generar un impacto significativo en el campo de la retina. Espero trabajar en colaboraci\u00f3n con el consejo y el equipo directivo para impulsar la innovaci\u00f3n y contribuir a la consecuci\u00f3n de nuestra misi\u00f3n compartida\u201d.\u201d<\/p>\n<p>M\u00e1s recientemente, el Sr. Sblendorio ocup\u00f3 varios puestos de liderazgo clave en IVERIC bio, Inc., una empresa de Astellas (anteriormente Ophthotech Corporation), incluidos los de director ejecutivo, presidente y director. Tambi\u00e9n se desempe\u00f1\u00f3 como vicepresidente ejecutivo, director de operaciones, director financiero y tesorero. Adem\u00e1s, se desempe\u00f1\u00f3 como presidente, director financiero y director en The Medicines Company y como vicepresidente ejecutivo y director financiero en Eyetech Pharmaceuticals. Al principio de su carrera, el Sr. Sblendorio fue director general de MPM Capital Advisors, LLC y ocup\u00f3 varios puestos financieros senior en Hoffman-La Roche.<\/p>\n<p>La directora ejecutiva y cofundadora de Nanoscope, Sulagna Bhattacharya, expres\u00f3 su entusiasmo por el nombramiento: \u201cNos complace dar la bienvenida a Glenn Sblendorio como presidente de nuestro consejo de administraci\u00f3n. Su vasta experiencia en la creaci\u00f3n y el crecimiento de empresas innovadoras, junto con su profundo conocimiento del \u00e9xito en la comercializaci\u00f3n de tratamientos para la retina, sin duda fortalecer\u00e1 la posici\u00f3n de Nanoscope como l\u00edder en la industria oftalmol\u00f3gica. Esperamos aprovechar su experiencia a medida que avanzamos en las pr\u00f3ximas fases de nuestro desarrollo\u201d.\u201d<\/p>\n<p>El Sr. Sblendorio se une a la compa\u00f1\u00eda en un momento crucial, y su nombramiento refleja el compromiso de Nanoscope de optimizar el impacto del consejo de administraci\u00f3n mediante la creaci\u00f3n de un grupo de asesores diversos y altamente cualificados que impulsen la innovaci\u00f3n y el \u00e9xito de la organizaci\u00f3n. Nanoscope se dedica a ser pionera en soluciones retinianas innovadoras que generen un impacto duradero para pacientes y m\u00e9dicos.<\/p>\n<p><strong>Acerca del nanoscopio<br \/>\n<\/strong><a href=\"https:\/\/nanostherapeutics.com\/es\/\">www.nanostherapeutics.com<\/a><strong><br \/>\n<\/strong>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la vista y son independientes de los genes para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El activo principal de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados principales del ensayo cl\u00ednico RESTORE Fase 2b, multic\u00e9ntrico, aleatorizado, de doble enmascaramiento y controlado de forma simulada en los EE. UU. para la retinitis pigmentosa.\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4008321-1&h=4175393640&u=https%3A%2F%2Fclassic.clinicaltrials.gov%2Fct2%2Fshow%2FNCT04945772%3Fterm%3DNanoscope%26draw%3D2&a=(NCT04945772)\">(NCT04945772)<\/a>. La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes de Stargardt.\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4008321-1&h=757890473&u=http%3A%2F%2Finicaltrials.gov%2Fct2%2Fshow%2FNCT05417126%3Fterm%3Dnanoscope%26draw%3D2&a=(NCT05417126)\">(NCT05417126)<\/a>. MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n<p><strong>Para consultas de los medios, comun\u00edquese con:<\/strong><br \/>\nSocios Argot<br \/>\n212-600-1902<br \/>\n<a href=\"mailto:PR@nanostherapeutics.com?subject=Chairman%20of%20the%20Board%20Appointment\">PR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>New Addition Highlights Continued Enhancement of Organization\u2019s Strategic Trajector Dallas, TX \u2013 December 4, 2023 \u2013 Nanoscope Therapeutics (Nanoscope), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately. With more than 30 years of exemplary experience marked by extensive [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5573,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5571","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-04T11:44:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:27:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_Sblendorio1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_Sblendorio1.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/04\\\/glenn-sblendorio-as-chairman-of-the-board\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/04\\\/glenn-sblendorio-as-chairman-of-the-board\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board\",\"datePublished\":\"2023-12-04T11:44:28+00:00\",\"dateModified\":\"2025-06-27T16:27:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/04\\\/glenn-sblendorio-as-chairman-of-the-board\\\/\"},\"wordCount\":547,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/04\\\/glenn-sblendorio-as-chairman-of-the-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/NSCOPE_LI_Sblendorio1.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/04\\\/glenn-sblendorio-as-chairman-of-the-board\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/04\\\/glenn-sblendorio-as-chairman-of-the-board\\\/\",\"name\":\"Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/04\\\/glenn-sblendorio-as-chairman-of-the-board\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/04\\\/glenn-sblendorio-as-chairman-of-the-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/NSCOPE_LI_Sblendorio1.jpg\",\"datePublished\":\"2023-12-04T11:44:28+00:00\",\"dateModified\":\"2025-06-27T16:27:04+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/04\\\/glenn-sblendorio-as-chairman-of-the-board\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/04\\\/glenn-sblendorio-as-chairman-of-the-board\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/04\\\/glenn-sblendorio-as-chairman-of-the-board\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/NSCOPE_LI_Sblendorio1.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/NSCOPE_LI_Sblendorio1.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/04\\\/glenn-sblendorio-as-chairman-of-the-board\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics contin\u00faa su crecimiento en liderazgo; da la bienvenida a Glenn Sblendorio, un destacado l\u00edder en finanzas y biotecnolog\u00eda, como presidente de la junta directiva.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2023-12-04T11:44:28+00:00","article_modified_time":"2025-06-27T16:27:04+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_Sblendorio1.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_Sblendorio1.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board","datePublished":"2023-12-04T11:44:28+00:00","dateModified":"2025-06-27T16:27:04+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/"},"wordCount":547,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_Sblendorio1.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/","url":"https:\/\/nanostherapeutics.com\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/","name":"Nanoscope Therapeutics contin\u00faa su crecimiento en liderazgo; da la bienvenida a Glenn Sblendorio, un destacado l\u00edder en finanzas y biotecnolog\u00eda, como presidente de la junta directiva.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_Sblendorio1.jpg","datePublished":"2023-12-04T11:44:28+00:00","dateModified":"2025-06-27T16:27:04+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_Sblendorio1.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_Sblendorio1.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2023\/12\/04\/glenn-sblendorio-as-chairman-of-the-board\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5571"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5571\/revisions"}],"predecessor-version":[{"id":9060,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5571\/revisions\/9060"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5573"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}